Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Routine lipid panel monitoring ups statin adherence

Stephen Padilla
19 Oct 2019

Routine evaluation using lipid panels improves adherence to statin medication among patients with atherosclerotic cardiovascular disease, a new study reports.

Researchers enrolled 813,887 patients who were on statin therapy, of whom 52,583 were new statin users. Adherence to medication was determined using medication refill data and evaluated by proportion of days covered (PDC). Those on multiple statins, with unknown medication dosage and who had limited life expectancy, were ineligible.

At the index visit, majority of the participants (43.9 percent) were on moderate-intensity statin therapy; 23.9 percent were receiving high-intensity therapy, while only 8.8 percent were on low-intensity statins. The mean number of panels ordered was 1.54±1.04 per patient. More than 20 percent of patients were not on any statin therapy.

The mean PDC for all patients on statins during the study period was 79.9±24.6 percent, and 65.5 percent had PDC ≥80 percent. Disaggregation of the analysis found that the rate of PDC ≥80 percent was significantly greater in those with at least one lipid panel than those without (66.0 percent vs 61.2 percent; p<0.0001).

A total of 131,595 patients required a change in statin dose over the study duration. In these patients, the rate of PDC ≥80 percent remained significantly elevated in those who had undergone lipid panel monitoring within 4–12 weeks of the dose adjustments (66.3 percent vs 61.8 percent; p<0.0001).

This pattern of effect on PDC ≥80 percent remained significant even when analysis was restricted to the new statin users (with vs without lipid panel: 58.6 percent vs 49.8 percent; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.